1. Home
  2. GLBS vs BOLD Comparison

GLBS vs BOLD Comparison

Compare GLBS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globus Maritime Limited

GLBS

Globus Maritime Limited

HOLD

Current Price

$3.07

Market Cap

65.4M

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.43

Market Cap

60.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLBS
BOLD
Founded
2006
2018
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
65.4M
60.8M
IPO Year
2010
2024

Fundamental Metrics

Financial Performance
Metric
GLBS
BOLD
Price
$3.07
$2.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
129.7K
★ 199.4K
Earning Date
11-27-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$39.12
N/A
Revenue Next Year
$2.76
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$0.96
52 Week High
$4.06
$3.16

Technical Indicators

Market Signals
Indicator
GLBS
BOLD
Relative Strength Index (RSI) 38.57 37.70
Support Level $2.71 $1.40
Resistance Level $3.19 $2.71
Average True Range (ATR) 0.21 0.16
MACD -0.03 -0.01
Stochastic Oscillator 24.24 25.58

Price Performance

Historical Comparison
GLBS
BOLD

About GLBS Globus Maritime Limited

Globus Maritime Ltd is a dry bulk shipping company that provides marine transportation services internationally. The company owns, operates, and manages a fleet of dry bulk vessels that transport iron ore, coal, grain, steel products, cement, alumina, and other dry bulk cargo. Its operations are managed by its subsidiary which also provides in-house commercial and technical management for its vessels and also offers consulting services for an affiliated ship management company. It generates maximum revenues by charging customers for the use of vessels to transport dry bulk commodities.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: